Drug Profile
Research programme: Nanobodies therapeutics - Ablynx/Boehringer Ingelheim
Latest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator Ablynx
- Class Antineoplastics; Bispecific antibodies; Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Autoimmune disorders; Cancer; Respiratory tract disorders
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for preclinical development in Cancer in Belgium (Parenteral)
- 28 Mar 2023 No recent reports of development identified for preclinical development in Cancer in Germany (Parenteral)
- 11 Mar 2021 Phase-II development is ongoing in Belgium and phase I development in Germany (Parenteral) in Cancer